STAT+: What’s the deal with Isomorphic Labs?
Reported by STAT News · all stories from statnews.com
Editorial digest
An analysis from STAT News explores the trajectory and business strategy of Isomorphic Labs. The piece reviews how the computational drug design venture is progressing within the biopharma landscape.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/14/2026
STAT+: The startup chasing ‘general biological intelligence’
A new company is pursuing advanced biological AI capabilities.
- Trusted health newsroom9/2/2026
STAT+: How a former ARPA-H director’s startup is tackling AI’s ‘dumb problems’
A startup led by a former ARPA-H director is addressing common AI challenges.
- Trusted health newsroom10/8/2026
STAT+: Why this startup is taking its AI to predict breast cancer risk directly to patients
A startup is offering AI-driven breast cancer risk assessment directly to individuals.
- Trusted health newsroom8/26/2026
STAT+: AI biotech Insitro’s Daphne Koller on how to speed up clinical trials
Daphne Koller from Insitro discusses using artificial intelligence to accelerate clinical studies.
- Trusted health newsroom8/13/2026
STAT+: An investigation into Commure, and Medicare’s new-tech incentives for AI devices
An investigation examines Commure and Medicare's AI device incentives.
- Trusted health newsroom10/20/2026
Why I wish you didn’t want to see Nathan Fielder’s Elizabeth Holmes documentary
A commentator reflects on audience fascination with Nathan Fielder's new documentary project about Elizabeth Holmes.